Therapeutic vaccine for the treatment of papillomavirus lesions
AssigneeRicardo Rosales Ledezma
InventorRicardo Rosales Ledezma
Life of this patent
Estimating the term…
Abstract
A novel attenuated vaccinia virus GAB-1 and its use in treatment of papillomavirus lesions. In preferred embodiments, the Lederle-Chorioallantoic strain of vaccinia virus is serially passaged in chicken embryo-fibroblast (CEF) cells by at least 100 passages. Surprisingly, GAB-1 is highly immunogenic after serial passaging, while being less virulent and safe to use without side effects. Experimentation has found that GAB-1 is much more immunogenic than other strains of vaccinia virus, including Western Reserve (WR) and modified Vaccinia Ankara (MVA). GAB-1 can be used safely in humans for treating tumorous lesions caused by human papillomavirus (HPV).
Claims8
A method of treating a cancer in an individual, comprising:
- administering a therapeutically effective amount of a pharmaceutical composition comprising the attenuated Lederle-Chorioallantoic GAB-1 strain of vaccinia virus to the individual, wherein the cancer is caused by human papillomavirus.
A method of treating a lesion caused by human papilloma virus (HPV) in an individual, comprising:
- administering a therapeutically effective amount of a pharmaceutical composition comprising the attenuated Lederle-Chorioallantoic GAB-1 strain of vaccinia virus to the individual.
Dependencies are inferred from the claim text.